PT3126391T - Anticorpos contra hpa-1a - Google Patents

Anticorpos contra hpa-1a

Info

Publication number
PT3126391T
PT3126391T PT157137498T PT15713749T PT3126391T PT 3126391 T PT3126391 T PT 3126391T PT 157137498 T PT157137498 T PT 157137498T PT 15713749 T PT15713749 T PT 15713749T PT 3126391 T PT3126391 T PT 3126391T
Authority
PT
Portugal
Prior art keywords
antibodies against
against hpa
hpa
antibodies
Prior art date
Application number
PT157137498T
Other languages
English (en)
Inventor
Michaelsen Terje
Ihle Oistein
Brynjar Stuge Tor
Husebekk Anne
TILLER Heidi
Eksteen Mariana
Ragnar Skogen Bjorn
Original Assignee
Univ Hospital Of North Norway
Norinnova Tech Transfer As
Univ I Tromso Norges Arktiske Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1405775.6A external-priority patent/GB201405775D0/en
Priority claimed from GBGB1417614.3A external-priority patent/GB201417614D0/en
Application filed by Univ Hospital Of North Norway, Norinnova Tech Transfer As, Univ I Tromso Norges Arktiske Univ filed Critical Univ Hospital Of North Norway
Publication of PT3126391T publication Critical patent/PT3126391T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/38Pediatrics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT157137498T 2014-03-31 2015-03-31 Anticorpos contra hpa-1a PT3126391T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1405775.6A GB201405775D0 (en) 2014-03-31 2014-03-31 Antibodies
GBGB1417614.3A GB201417614D0 (en) 2014-10-06 2014-10-06 Antibodies

Publications (1)

Publication Number Publication Date
PT3126391T true PT3126391T (pt) 2019-11-27

Family

ID=52785093

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157137498T PT3126391T (pt) 2014-03-31 2015-03-31 Anticorpos contra hpa-1a

Country Status (21)

Country Link
US (2) US10882919B2 (pt)
EP (1) EP3126391B1 (pt)
AU (1) AU2015239606C1 (pt)
BR (1) BR112016022508A2 (pt)
CA (1) CA2943857C (pt)
CY (1) CY1122728T1 (pt)
DK (1) DK3126391T3 (pt)
ES (1) ES2757596T3 (pt)
HR (1) HRP20192097T1 (pt)
HU (1) HUE047455T2 (pt)
IL (1) IL247988B1 (pt)
LT (1) LT3126391T (pt)
ME (1) ME03655B (pt)
MX (1) MX2016012620A (pt)
NZ (1) NZ724772A (pt)
PL (1) PL3126391T3 (pt)
PT (1) PT3126391T (pt)
RS (1) RS59704B1 (pt)
RU (1) RU2688627C2 (pt)
SI (1) SI3126391T1 (pt)
WO (1) WO2015150417A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022212930A1 (en) * 2021-04-02 2022-10-06 Rallybio Ipa, Llc Method of administering anti-hpa-1a gamma globulin
CA3224173A1 (en) * 2021-07-01 2023-01-05 Rallybio Ipa, Llc Method of administering anti-hpa-1a monoclonal antibody
AU2022305071A1 (en) * 2021-07-01 2024-01-18 Rallybio Ipa, Llc Administration of anti-hpa-1a antibodies
CA3235140A1 (en) * 2021-11-08 2023-05-11 Douglas L. Sheridan Assays for quantification of anti-hpa-1a antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
GB9223390D0 (en) 1992-11-07 1992-12-23 Common Services Agency Anti-hpa1 testing
GB9505447D0 (en) 1995-03-17 1995-05-03 Common Services Agency Competitive binding assay
WO1998055146A1 (en) 1997-06-05 1998-12-10 Johns Hopkins University IDENTIFICATION OF HUMAN HEAVY CHAIN ANTIBODY FRAGMENT DIRECTED AGAINST HUMAN PLATELET ALLOANTIGEN 1a(HPA-1a)
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030027207A1 (en) 2000-02-29 2003-02-06 Filpula David Ray Anti-platelet binding proteins and polymer conjugates containing the same
JP3312204B2 (ja) 2000-10-17 2002-08-05 学校法人 慶應義塾 血小板減少症の診断用キット
GB0315754D0 (en) 2003-07-04 2003-08-13 Univ Aberdeen Pharmaceutical compositions
US20080261205A1 (en) 2004-02-06 2008-10-23 Canadian Blood Services Method for the Simultaneous Determination of Blood Group and Platelet Antigen Genotypes
CA2590164A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
NO345593B1 (no) 2005-07-18 2021-05-03 Amgen Inc Humane anti-B7RP1 nøytraliserende antistoffer
US20090317413A1 (en) * 2005-11-15 2009-12-24 Cambridge Enterprise Limited Detection of human platelet antigen (hpa) antibodies
US8840897B2 (en) 2006-01-03 2014-09-23 Prophylix Pharma As Preparation useful for, and method for treatment of neonatal alloimmune thrombocytopenia (NAIT)
JP5042237B2 (ja) 2006-02-07 2012-10-03 スティフチュンク フュル ディアグノスティシュ フォルシュンク 血小板抗原特異抗体の結合を中和するペプチドアプタマー並びにそれを含む診断及び治療への応用
KR20080105111A (ko) 2006-02-28 2008-12-03 온코세라피 사이언스 가부시키가이샤 항 EphA4 항체의 효과기 기능을 이용한 세포 손상 방법
EP2006304A1 (en) * 2007-06-22 2008-12-24 Stiftung Für Diagnostische Forschung Anti-HPA-5b monoclonal antibody
KR101624357B1 (ko) 2007-05-25 2016-05-25 니혼 세키쥬지샤 신규한 GPIIIa 유전자
EP2025685B1 (en) 2007-08-15 2013-06-19 Canadian Blood Services Monoclonal antibodies against BETA3 integrins
EP2450381B1 (en) 2008-12-31 2019-07-03 Bharat Serums And Vaccines Ltd. Anti-RHD monoclonal antibodies
CN101892314B (zh) 2010-06-22 2012-04-18 天津市秀鹏生物技术开发有限公司 用于检测人血小板同种抗原基因的引物组及试剂盒
NO2796881T3 (pt) * 2013-04-26 2018-03-31

Also Published As

Publication number Publication date
MX2016012620A (es) 2017-04-06
ES2757596T3 (es) 2020-04-29
CA2943857C (en) 2023-07-11
US20210189005A1 (en) 2021-06-24
IL247988A0 (en) 2016-11-30
US20170121422A1 (en) 2017-05-04
LT3126391T (lt) 2020-02-10
EP3126391B1 (en) 2019-08-21
DK3126391T3 (da) 2019-11-25
RU2688627C2 (ru) 2019-05-22
HUE047455T2 (hu) 2020-04-28
AU2015239606A1 (en) 2016-10-20
RU2016142718A (ru) 2018-05-07
RU2016142718A3 (pt) 2018-10-18
RS59704B1 (sr) 2020-01-31
SI3126391T1 (sl) 2020-04-30
BR112016022508A2 (pt) 2017-10-10
AU2015239606C1 (en) 2020-08-27
CY1122728T1 (el) 2021-03-12
CA2943857A1 (en) 2015-10-08
US10882919B2 (en) 2021-01-05
US11725063B2 (en) 2023-08-15
EP3126391A1 (en) 2017-02-08
PL3126391T3 (pl) 2020-05-18
AU2015239606B2 (en) 2020-06-04
NZ724772A (en) 2023-03-31
WO2015150417A1 (en) 2015-10-08
HRP20192097T1 (hr) 2020-04-03
ME03655B (me) 2020-07-20
IL247988B1 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
IL252004B (en) Ether-substituted antibody
IL250583A0 (en) Anti-tigit antibodies
SG11201703403TA (en) Anti-tim-3 antibodies
SG11201703346PA (en) Anti-tim-3 antibodies
IL252422B (en) Effector-deficient anti-cd32a antibodies
IL291164A (en) Anti-nme antibody
IL250374A0 (en) Antibodies against ceramide
IL246603B (en) A new antibody against netrin-1
GB201410520D0 (en) Antibody
SG11201700922YA (en) Anti-orai1 antibody
PL3628731T3 (pl) Nowe przeciwciało przeciwko presepsynie
IL247988A0 (en) Antibodies against hpa–1a
GB201419089D0 (en) Anti-TIM-3 antibodies
GB201419092D0 (en) Anti-TIM-3 antibodies
GB201417614D0 (en) Antibodies
GB201414270D0 (en) Antibodies
GB201418776D0 (en) Antibody
GB201413745D0 (en) Antibody
GB201405775D0 (en) Antibodies
GB201411319D0 (en) Antibody
GB201401200D0 (en) Antibodies
GB201407535D0 (en) Antibody Drug - Conjugates